Trent Munro

Professor Munro has over 25 years’ research and development experience, including with multinational biopharmaceutical company Amgen. During this time which included the role of Executive Director leading a global team, Professor Munro played key roles in the translation of molecules from research, through clinical trials, regulatory approval, and global licensure. This included a diverse range of programs spanning novel biologics, small molecules, nucleic acid-based, cell-based and gene-based therapies across multiple therapeutic areas. As Senior Vice President of Therapeutics at Microba Life Sciences, Professor Munro leads the Company’s therapeutic strategy to progress its drug development programs and pharma partnering engagements. Prior to joining Microba, Professor Munro held several leadership roles in Australia including Director of the National Biologics Facility (NBF), Program Director of the CEPI funded Rapid Response Vaccine pipeline, Director of the ARC Centre for Biopharmaceutical Innovation (CBI) and Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland. Professor Munro completed postdoctoral studies in cell biology and developmental genetics at Harvard Medical School and the University of Cambridge and has a PhD in Protein Biochemistry from the University of Queensland.